Related Experiment Videos
[Allergy to chymopapain: value of predictive tests before chemonucleolysis]
Annales Francaises D'Anesthesie Et De Reanimation
|January 1, 1985
Summary
Chemonucleolysis using chymopapain carries anaphylaxis risk for sensitive individuals. Predictive immuno-allergological screening, including skin prick tests and histamine release tests, can identify at-risk patients before treatment.
Area of Science:
- Allergology
- Immunology
- Enzymology
Background:
- Chemonucleolysis, utilizing chymopapain from Carica papaya, treats vertebral disc hernias.
- A subset of the population (approx. 1%) has latent sensitivity to chymopapain, posing a risk of severe anaphylaxis.
- Risk factors for anaphylaxis include atopy and prior allergies to foods or drugs.